newsfilter
← Latest News
Business Wire·

NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic for Prostate Cancer

Available within NEO PanTracer™ Pro for prostate cancer and as a standalone test, PTEN IHC CDx identifies patients who may be eligible for TRUQAP® NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology